Related Experiment Videos
[An anticancer drug--carboquone].
1Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1988
Summary
Carboquone (CQ), an alkylating agent, shows excellent antitumor efficacy but severe side effects. Combination therapy with cis-Platinum and prednisone (PPQ) demonstrated a 30% response rate, broadening its anticancer spectrum.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Context:
- Carboquone (CQ) is an alkylating agent developed in 1970.
- CQ exhibits potent antitumor activity but is associated with significant side effects.
- Research aims to enhance CQ's efficacy and mitigate its adverse effects through modified treatment regimens.
Purpose:
- To evaluate the efficacy and tolerability of a combination chemotherapy regimen involving Carboquone (CQ), cis-Platinum, and prednisone (PPQ).
- To explore strategies for improving the therapeutic index of Carboquone in cancer treatment.
Summary:
- The PPQ therapy regimen involves administering CQ (7 mg/m2 IV on day 1), cis-Platinum (20 mg/body IV on days 1-5), and prednisone (3.0 mg PO on days 1-5).
- This combination therapy has shown a response rate of approximately 30% in preliminary studies.
- The study also notes that Carboquone's antitumor spectrum has been reported to broaden with such combined approaches.
Impact:
- The PPQ regimen offers a potential strategy to improve cancer treatment outcomes by enhancing antineoplastic activity.
- This approach may help manage the side effects associated with Carboquone, improving patient tolerability.
- Findings contribute to the understanding of combination chemotherapy and the development of more effective cancer therapies.